相关实验视频

Updated: Jun 12, 2026

Generation of Standardized and Reproducible Forebrain-type Cerebral Organoids from Human Induced Pluripotent Stem Cells
10:25

Generation of Standardized and Reproducible Forebrain-type Cerebral Organoids from Human Induced Pluripotent Stem Cells

Published on: January 23, 2018

22.3K

同源性皮质器官可以精确地准阿尔茨海默氏症疾病中APP变异特异性途径

T Grass, I M Cosacak, A Ordureau

    bioRxiv : the preprint server for biology
    |February 27, 2026
    PubMed
    概括

    这项研究使用阿尔茨海默病 (AD) 器官模型来揭示变异特异性疾病途径. 针对性疗法,如TFEB激活或铁灭抑制,显示了个性化的AD治疗的希望.

    更多相关视频

    Robust and Highly Reproducible Generation of Cortical Brain Organoids for Modelling Brain Neuronal Senescence In Vitro05:40

    Robust and Highly Reproducible Generation of Cortical Brain Organoids for Modelling Brain Neuronal Senescence In Vitro

    Published on: May 5, 2022

    4.6K
    Author Spotlight: Targeted Microinjection and Electroporation of Primate Cerebral Organoids for Genetic Modification11:44

    Author Spotlight: Targeted Microinjection and Electroporation of Primate Cerebral Organoids for Genetic Modification

    Published on: March 24, 2023

    5.1K

    相关概念视频

    Alzheimer's Disease: Overview01:26

    Alzheimer's Disease: Overview

    Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
    The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
    Alzheimer's Disease: Treatment01:22

    Alzheimer's Disease: Treatment

    Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
    Alzheimer Disease l: Introduction01:29

    Alzheimer Disease l: Introduction

    Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
    Alzheimer Disease ll: Pathophysiology01:23

    Alzheimer Disease ll: Pathophysiology

    Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...